Tumour-associated trypsin inhibitor in ovarian cancer
Author Information
Author(s): H. Halila, P. Lehtovirta, U.-H. Stenman
Primary Institution: Helsinki University Central Hospital
Hypothesis
The study evaluates the usefulness of serum and urine TATI levels in the diagnosis and monitoring of patients with ovarian cancer.
Conclusion
TATI levels in urine are more useful than serum levels for monitoring mucinous ovarian cancer, but CA 125 remains the best marker for non-mucinous types.
Supporting Evidence
- Preoperative urine TATI was elevated in 55% of patients.
- Serum TATI was elevated in 45% of samples from patients with clinical evidence of disease.
- TATI levels correlated with disease progression in some patients.
Takeaway
Doctors looked at a special protein in the urine of women with ovarian cancer to see if it could help find the disease or track how well treatment is working.
Methodology
The study analyzed serum and urine samples from 102 patients with ovarian cancer, comparing TATI levels with clinical stage and histopathologic type.
Limitations
The study did not provide better information for non-mucinous ovarian cancer compared to CA 125 alone.
Participant Demographics
Patients aged 19 to 82 years, median age 59, with various histological diagnoses and stages of ovarian cancer.
Want to read the original?
Access the complete publication on the publisher's website